Opinion|Videos|November 20, 2026

HER2-Mutant NSCLC: Trastuzumab Deruxtecan for HER2 Overexpression

In this segment of the OncLive Peer Exchange®, Dr. Benjamin P. Levy, Dr. Julia Rotow, and Dr. Narjust Florez discuss the role of trastuzumab deruxtecan (T-DXd) in HER2-overexpressing non-small cell lung cancer (NSCLC), including patients whose tumors demonstrate HER2 IHC 3+ expression.

In this segment of the OncLive Peer Exchange®, Dr. Benjamin P. Levy, Dr. Julia Rotow, and Dr. Narjust Florez discuss the role of trastuzumab deruxtecan (T-DXd) in HER2-overexpressing non-small cell lung cancer (NSCLC), including patients whose tumors demonstrate HER2 IHC 3+ expression. Dr. Levy highlights the potential value of this treatment option for patients without an actionable genomic driver or who have exhausted available targeted therapies and progressed after chemotherapy and immunotherapy. Dr. Rotow emphasizes the importance of reassessing tumor biology at progression, particularly in patients previously treated with targeted therapies, to identify potentially actionable changes. Dr. Florez shares clinical experiences using T-DXd in patients with HER2 overexpression, including patients with EGFR-mutant disease who have progressed through multiple treatment lines. The panel discusses meaningful responses observed in selected patients and the potential to expand treatment options for those with limited alternatives. They also reflect on how advances in biomarker testing and targeted therapies are enabling increasingly personalized treatment decisions in NSCLC.


Related to this article